SynCore Biotechnology Co., Ltd. (4192) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for SynCore Biotechnology Co., Ltd. (4192:TWSE), powered by AI.

Current Price
$20.55
Sector
Healthcare
What is the SynCore Biotechnology Co., Ltd. stock price forecast?

SynCore Biotechnology Co., Ltd. is currently trading at $20.55. View real-time AI analysis on Alpha Lenz.

What is SynCore Biotechnology Co., Ltd. insider trading activity?

View the latest insider trading data for SynCore Biotechnology Co., Ltd. on Alpha Lenz.

What is SynCore Biotechnology Co., Ltd.'s P/E ratio?

View SynCore Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.

SynCore Biotechnology Co., Ltd.

TWSE · 4192
NT$20.55+0.05(+0.24%)
Ask about SynCore Biotechnology Co., Ltd.'s future dividend policy...
Alpha Chat Insight

SynCore Biotechnology Co., Ltd.'s ROE is -16.9%. Explore profitability and growth together.

Ask for details

Company Overview

SynCore Biotechnology Co., Ltd. is a biopharmaceutical company based in Yilan, Taiwan, focused on the research, development, production, and commercialization of therapeutic drugs. Established in 2008 by Chih Wen Li, the company operates primarily within the health technology sector, with a specialization in major pharmaceuticals and biotechnology services. SynCore is engaged in a range of activities including novel drug discovery, food advisory, medicine inspection, and intellectual property management. Its portfolio features products such as SB03 Veregen, alongside the active development and clinical trial evaluation of anticancer therapeutics like SB01 in both injectable and oral formulations. With a workforce of approximately 40 employees, SynCore Biotechnology Co., Ltd. plays a significant role in Taiwan’s biotechnology and medical research industry, contributing to advancements in cancer treatment and allied pharmaceutical fields. The company distributes its products mainly within the domestic market, reinforcing its position in the Taiwanese life sciences landscape.

SectorHealthcare
IndustryBiotechnology
Employees40

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$27.04MRevenue
0.00Shares Out
40Employees

Margins

77.98%Gross
-103.55%EBITDA
-174.52%Operating
-169.19%Pre-Tax
-169.19%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

19.48%Rev 3Yr
15.19%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-15.96%ROA
-16.94%ROE
-15.90%ROIC

Financial Health

NT$157.33MCash & Cash Equivalents
NT$-147.26MNet Debt
4.10%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

SynCore Biotechnology Co., Ltd. (ticker: 4192) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 40 employees.

The current price is 20.55 with a P/E ratio of -x and P/B of -x.

ROE is -16.94% and operating margin is -174.52%. Annual revenue is $27M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
SynCore Biotechnology Co., Ltd. (4192) Stock Forecast 2026 $20.55 — Price, Financials & Analyst Targets | Alpha Lenz